OTCMKTS:PBSV - Pharma Bio Serv Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.04 0.00 (0.00 %) (As of 05/24/2019 11:49 AM ET)Previous Close$1.04Today's Range$1.04 - $1.0452-Week Range$0.4320 - $1.25VolumeN/AAverage Volume319 shsMarket Capitalization$24.34 millionP/E RatioN/ADividend Yield7.14%Beta0.24 ProfileChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico. Receive PBSV News and Ratings via Email Sign-up to receive the latest news and ratings for PBSV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Management consulting services Sub-IndustryN/A SectorBusiness Services Current SymbolOTCMKTS:PBSV Previous Symbol CUSIPN/A CIK1304161 Webhttp://www.pharmabioserv.com/ Phone787-278-2709Debt Debt-to-Equity RatioN/A Current Ratio11.38 Quick Ratio11.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio26.00 P/E GrowthN/A Sales & Book Value Annual Sales$17.80 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book1.20Profitability EPS (Most Recent Fiscal Year)($0.05) Net Income$1.27 million Net Margins23.60% Return on Equity8.63% Return on Assets6.95%Miscellaneous Employees185 Outstanding Shares23,400,000Market Cap$24.34 million Next Earnings Date6/13/2019 (Estimated) OptionableNot Optionable Pharma Bio Serv (OTCMKTS:PBSV) Frequently Asked Questions What is Pharma Bio Serv's stock symbol? Pharma Bio Serv trades on the OTCMKTS under the ticker symbol "PBSV." When is Pharma Bio Serv's next earnings date? Pharma Bio Serv is scheduled to release their next quarterly earnings announcement on Thursday, June 13th 2019. View Earnings Estimates for Pharma Bio Serv. Has Pharma Bio Serv been receiving favorable news coverage? Media stories about PBSV stock have been trending positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pharma Bio Serv earned a news impact score of 2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Pharma Bio Serv's key competitors? Some companies that are related to Pharma Bio Serv include China Internet Nationwide Fncl Srvcs (CIFS), Lightbridge (LTBR), Wilhelmina International (WHLM), Gopher Protocol (GOPH), TSS (TSSI), Digipath (DIGP), Transatlantic Capital (TACI), HPIL (HPIL), Cartesian (CRTN), China Xingbang Industry Group (CXGP), CleanTech Innovations (SIXD) and Green Energy Management Services (GRMS). What other stocks do shareholders of Pharma Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), Aeglea Bio Therapeutics (AGLE), AstroNova (ALOT), Mondelez International (MDLZ), Lendingtree (TREE), Transcat (TRNS), Wheeler Real Estate Investment Trust (WHLR), Yintech Investment (YIN) and Earthstone Energy (ESTE). Who are Pharma Bio Serv's key executives? Pharma Bio Serv's management team includes the folowing people: Ms. Elizabeth Plaza, Founder, Chairman & Sr. Strategic Consultant (Age 55)Mr. Victor Sanchez, CEO, Pres & Pres of European Operations (Age 48)Mr. Pedro J. Lasanta, CFO, VP of Fin. & Admin. and Sec. (Age 59) How do I buy shares of Pharma Bio Serv? Shares of PBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pharma Bio Serv's stock price today? One share of PBSV stock can currently be purchased for approximately $1.04. How big of a company is Pharma Bio Serv? Pharma Bio Serv has a market capitalization of $24.34 million and generates $17.80 million in revenue each year. The company earns $1.27 million in net income (profit) each year or ($0.05) on an earnings per share basis. Pharma Bio Serv employs 185 workers across the globe. What is Pharma Bio Serv's official website? The official website for Pharma Bio Serv is http://www.pharmabioserv.com/. How can I contact Pharma Bio Serv? Pharma Bio Serv's mailing address is Pharma-Bio Serv Building Suite 6 Road 696, DORADO PR, 00646. The company can be reached via phone at 787-278-2709 or via email at [email protected] MarketBeat Community Rating for Pharma Bio Serv (OTCMKTS PBSV)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 84 (Vote Outperform)Underperform Votes: 84 (Vote Underperform)Total Votes: 168MarketBeat's community ratings are surveys of what our community members think about Pharma Bio Serv and other stocks. Vote "Outperform" if you believe PBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBSV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Net Income Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.